Employers are trying to get more creative in the kinds of benefits packages they offer, but new regulations set up by the Affordable Care Act makes it difficult. One of the reasons for the changing market is the proliferation of plans with high deductibles, explained Leah Binder. As of yet, it’s unclear whether high deductibles are changing the market for the better or worse, she added.
However, one changing aspect of the health insurance market that Austin Frakt, PhD, views as a negative is the increased options in the marketplace. There is emerging evidence from the insurance marketplaces, and already established evidence from Medicare Part D and Medicare Advantage, that consumers are confused. This is especially a concern in the marketplaces where many consumers have never had insurance before.
“So when they go and they see a choice of 40 plans, different premiums, different deductibles across different time periods, different kinds of providers, copayments, and so forth, it’s enormously confusing,” he said. “They don’t know what their own costs or what the costs are going to be.”
Matt Salo directed the conversation toward provider risk in the new shared savings model. In Medicaid, he said, doctors are unsure how they can be held accountable for what happens outside the walls of their office if they do everything right inside it. But while providers cannot influence the behaviors of patients outside of their office, it’s only because they’ve never been given a financial incentive to do so before.
Binder pointed out that even though all the pieces are being put in place to change the way care is delivered, does not guarantee success.
“A handful of purchasers have been very interested in the ACO model and have actually started working directly with these ACOs to sort of work through some of these transition issues, because it doesn’t happen overnight,” she said. “Just because you say, ‘here’s the incentive on the table,’ everybody doesn’t suddenly change their behavior overnight.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More